{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:56:27Z","timestamp":1787756187964,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ando.2025.101701","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:58:03Z","timestamp":1736866683000},"page":"101701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chapter 12: Preparation for parathyroid surgery"],"prefix":"10.1016","volume":"86","author":[{"given":"Anne-Lise","family":"Lecoq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Cirenei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101701_bib0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"Ahmad","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0255","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ando.2025.101701_bib0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13613-019-0606-8","article-title":"Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients","volume":"9","author":"Mousseaux","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ando.2025.101701_bib0265","doi-asserted-by":"crossref","first-page":"R297","DOI":"10.1530\/EJE-17-0485","article-title":"Cardiovascular manifestations of primary hyperparathyroidism: a narrative review","volume":"177","author":"Pepe","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101701_bib0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/anec.12303","article-title":"High frequency of early repolarization and Brugada-type electrocardiograms in hypercalcemia","volume":"21","author":"Sonoda","year":"2016","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.ando.2025.101701_bib0275","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.0013-9580.2004.57003.x","article-title":"Vasoconstriction as the etiology of hypercalcemia-induced seizures","volume":"45","author":"Chen","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.ando.2025.101701_bib0280","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ando.2024.01.012","article-title":"Acute hypercalcemic crisis: a narrative review with a focus on pregnancy","volume":"85","author":"Sabbah","year":"2024","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101701_bib0285","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ando.2025.101701_bib0290","first-page":"473","article-title":"Rehydration in the treatment of severe hypercalcaemia","volume":"50","author":"Hosking","year":"1981","journal-title":"Q J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0295","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0300","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0305","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1049909111414164","article-title":"Modern management of malignant hypercalcemia","volume":"28","author":"Legrand","year":"2011","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.ando.2025.101701_bib0310","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM197010152831603","article-title":"Acute treatment of hypercalcemia with furosemide","volume":"283","author":"Suki","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2025.101701_bib0320","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101701_bib0325","first-page":"480","article-title":"Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism","volume":"110","author":"Jansson","year":"1991","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101701_bib0330","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJMcp1714213","article-title":"Primary hyperparathyroidism","volume":"379","author":"Insogna","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0335","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1159\/000189483","article-title":"Bisphosphonates prevent the hungry bone syndrome","volume":"74","author":"Kumar","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.ando.2025.101701_bib0340","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101701_bib0345","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"Vellanki","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0350","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"Kuchay","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0355","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2025.101701_bib0360","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101701_bib0365","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0370","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101701_bib0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"23","author":"Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ando.2025.101701_bib0380","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1530\/EC-20-0221","article-title":"Cinacalcet and primary hyperparathyroidism: systematic review and meta regression","volume":"9","author":"Ng","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2025.101701_bib0385","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0390","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ando.2025.101701_bib0395","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00298784","article-title":"Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy","volume":"50","author":"Fatemi","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ando.2025.101701_bib0400","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society Clinical Practice Guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0405","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jbmr.1869","article-title":"Calcitonin: physiology or fantasy?","volume":"28","author":"Davey","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101701_bib0410","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/bmj.1.5689.135","article-title":"Renal effects of calcitonin","volume":"1","author":"Cochran","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.ando.2025.101701_bib0415","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1007\/BF02553290","article-title":"Salmon calcitonin in the acute management of hypercalcemia","volume":"46","author":"Wisneski","year":"1990","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ando.2025.101701_bib0420","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7326\/0003-4819-93-2-269","article-title":"Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy","volume":"93","author":"Binstock","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2025.101701_bib0425","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ajem.2018.03.011","article-title":"Management of hypercalcaemic crisis in adults: current role of renal replacement therapy","volume":"36","author":"Bentata","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ando.2025.101701_bib0430","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0435","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1042\/cs0730659","article-title":"Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism","volume":"73","author":"Clements","year":"1987","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ando.2025.101701_bib0440","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2265.1992.tb02278.x","article-title":"The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency","volume":"37","author":"Clements","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2025.101701_bib0445","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0002-9343(99)00294-6","article-title":"The effects of vitamin D insufficiency in patients with primary hyperparathyroidism","volume":"107","author":"Silverberg","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ando.2025.101701_bib0450","first-page":"1054","article-title":"Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications","volume":"85","author":"Rao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0455","first-page":"N75","article-title":"Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective","volume":"17","author":"Rao","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101701_bib0460","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1210\/jc.2015-2022","article-title":"Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation","volume":"100","author":"Walker","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0465","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1210\/jc.2004-1772","article-title":"Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency","volume":"90","author":"Grey","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0470","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1210\/jc.2013-3978","article-title":"Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial","volume":"99","author":"Rolighed","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101701_bib0475","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/cen.12398","article-title":"Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature","volume":"80","author":"Shah","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2025.101701_bib0480","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.surg.2005.09.018","article-title":"25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy","volume":"138","author":"Stewart","year":"2005","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101701_bib0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-17-0416","article-title":"The impact of vitamin D status on hungry bone syndrome after surgery for primary hyperparathyroidism","volume":"178","author":"Kaderli","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101701_bib0490","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/jbmr.4682","article-title":"Management of primary hyperparathyroidism","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T20:10:47Z","timestamp":1740514247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0003426625000204"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101701","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chapter 12: Preparation for parathyroid surgery","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101701"}}